Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02095132 · ClinicalTrials.gov registry record · Phase 1
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT02095132: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02095132 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02095132, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan hydrochloride in treating younger patients with solid tumors that have come back (relapsed) or that have not responded to standard therapy (refractory). Adavosertib and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Irinotecan Hydrochloride
- DRUG Adavosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-03-28 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02095132
The ClinicalTrials.gov registry entry for NCT02095132 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan Hydrochloride is the first listed.
NCT02095132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02095132 about?
NCT02095132 is a clinical study titled "Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors". This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan hydrochloride in treating younger patients with solid tumors that have come back (relapsed) or that have not responded to standard therapy (refractory). Adavosertib and irinotecan hydrochloride may stop the gr...
What is the current status of trial NCT02095132?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2014-03-28. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT02095132?
The interventions under investigation include: Irinotecan Hydrochloride (DRUG), Adavosertib (DRUG).
Who is sponsoring clinical trial NCT02095132?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.